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Inactivating mutations of the melanocortin-4 receptor (MC4R) cause early-onset severe
obesity in humans. Comprehensive functional studies show that most of the inactivating
mutants of the MC4R are retained intracellularly. In the present study, we investigated
whether a small molecule inverse agonist of the MC4R, Ipsen 5i, could act as a pharma-
coperone and correct the cell surface expression and function of intracellularly retained
mutant MC4Rs using multiple cell lines, including HEK293 and two neuronal cell lines. We
showed that Ipsen 5i rescued the cell surface expression of all 11 intracellularly retained
mutant MC4Rs studied herein in at least one cell line. Ipsen 5i functionally rescued seven
mutants in all cell lines used. One mutant (Y157S) was functionally rescued in HEK293
cells but not in the two neuronal cell lines. Ipsen 5i increased cell surface expression of
three mutants (S58C, G98R, and F261S) but did not affect signaling. Ipsen 5i had no effect
on mutant MC4Rs with other defects (∆88-92, D90N, I102S) or no defect (N274S). It also
did not affect trafficking of a misrouted MC3R mutant (I335S). Cell impermeable peptide
ligands of the MC4R or cell permeable small molecule ligand of δ opioid receptor could
not rescue misrouted mutant MC4R. In summary, we demonstrated that Ipsen 5i was a
novel potent pharmacoperone of the MC4R, correcting trafficking and signaling of a sig-
nificant portion (73%) of intracellularly retained mutants. Additional studies are needed to
demonstrate its in vivo efficacy.
Keywords: G protein-coupled receptor, melanocortin-4 receptor, obesity, pharmacological chaperone/
pharmacoperone, protein misfolding
INTRODUCTION
The melanocortin-4 receptor (MC4R) is a G protein-coupled
receptor (GPCR) that is widely expressed in the central nervous
system including the cortex, thalamus, hypothalamus, hippocam-
pus, brainstem, and spinal cord (1, 2). The MC4R plays a vital role
in the leptin-melanocortin pathway in regulating energy home-
ostasis, affecting both energy intake and expenditure (3, 4). Tissue-
specific knockout studies revealed that the MC4R expressed in the
paraventricular nucleus and/or amygdala neurons regulates food
intake (5) whereas the MC4R expressed in the cholinergic neurons
regulates energy expenditure and hepatic glucose production (6).
Inactivating mutations of the MC4R cause early-onset severe obe-
sity (7–9), which is the most common monogenic form of obesity
in humans (10).
Most of the inactivating MC4R mutants are misfolded and
trapped intracellularly by the stringent endoplasmic reticulum
(ER) quality control system (11–13). These mutant MC4Rs may
only have minor folding defect but retain pharmacological func-
tion. If they are escorted onto the cell surface, they can poten-
tially bind the ligand and initiate signaling. Several studies have
attempted to promote the anterograde trafficking of these mutant
Abbreviations: DMSO, dimethyl sulfoxide; ER, endoplasmic reticulum; GPCR, G
protein-coupled receptor; HEK, human embryonic kidney; MC3R, melanocortin-3
receptor; MC4R, melanocortin-4 receptor; MSH, melanocyte stimulating hormone;
WT, wild type.
MC4Rs, using molecular chaperone (14), chemical chaperone
(15), or pharmacological chaperone (or pharmacoperone) (13,
16–18).
The therapeutic potential of molecular and chemical chaper-
ones is limited due to disruption of proteostasis or significant side
effects whereas pharmacoperone is a promising approach. It has
been tested in numerous human diseases caused by misfolded pro-
teins, including neurodegenerative diseases, cystic fibrosis, lysoso-
mal storage diseases, and cancer, with several promising clinical
trials underway [reviewed in Ref. (19–21)]. Misfolding is also the
most common defect in diseases caused by mutations in GPCR
genes (22). Pharmacoperones have also been identified for sev-
eral GPCRs, including rhodopsin, V2 arginine vasopressin recep-
tor, gonadotropin-releasing hormone receptor, calcium-sensing
receptor, and others [reviewed in Ref. (21)]. In the MC4R, we
and others reported a few molecules that act as pharmacoperones
(13, 16–18). These compounds have low affinities for the MC4R,
therefore, usually need high concentrations (10−6 M and higher)
to achieve any rescue.
Ipsen 5i was synthesized and identified as a high-affinity
antagonist and partial inverse agonist of MC4R competing with
[Nle4,D-Phe7]-α-melanocyte stimulating hormone (NDP-MSH)
for binding to the MC4R (23–25). We reported recently that
although it decreases basal signaling at the classical Gs-cAMP path-
way, it acts as an agonist in the mitogen-activated protein kinase
pathway (26). In this study, we investigated whether Ipsen 5i could
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act as a pharmacoperone promoting the proper folding and traf-
ficking of intracellularly retained mutant MC4Rs using multiple
cell lines. A total of 15 mutants were studied, including 11 (S58C,
N62S, I69R, P78L, C84R, G98R, Y157S, W174C, P260Q, F261S,
and C271Y) that are retained intracellularly and four (∆88-92,
D90N, I102S, and N274S) that are expressed relatively normally at
the cell surface with other or no defects.
MATERIALS AND METHODS
MATERIALS AND PLASMIDS
NDP-MSH was purchased from Peptides International (Louisville,
KY),α-MSH from Pi Proteomics (Huntsville, AL, USA), SHU9119
from Tocris Bioscience (Ellisville, MO, USA), and naltrexone
hydrochloride from Alfa Aesar (Ward Hill, MA, USA). Ipsen 5i
was custom synthesized by Enzo Life Science (Plymouth Meeting,
PA, USA). [125I]-cAMP was iodinated with chloramine T method
(25). Wild type (WT) and mutant human MC4R with N-terminal
c-myc tag and human melanocortin-3 receptor (MC3R) with N-
terminal 3×HA tag were previously constructed and sequenced
(16, 27–30).
CELL CULTURE AND TRANSFECTION
Human embryonic kidney (HEK) 293,Neuro2a,and N1E-115 cells
were purchased from American Type Culture Collection (Manas-
sas,VA, USA) and cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% newborn calf serum (HEK293 cells) or
10% fetal bovine serum (Neuro2a and N1E-115 cells) at 37°C.
HEK293 cells were stably transfected using calcium phosphate
precipitation method for transfection and 0.2 mg/ml G418 for
selection. Neuro2a and N1E-115 cells were transiently transfected
using jetPRIME transfection reagent (Polyplus-transfection, New
York, NY, USA) and approximately 24 h later were used for lig-
and treatment. Cells were treated with indicated concentrations
of ligands or 0.1% dimethyl sulfoxide (DMSO) as control for 24 h
at 37°C. All cell culture plates were pretreated with 0.1% gelatin
before cell plating unless noted otherwise.
CONFOCAL MICROSCOPY
HEK293 stable cells seeded into poly-d-lysine-coated 8-well slides
(Biocoat Cellware from Falcon, B&D Systems, Franklin Lakes,
NJ, USA) were treated with 0.1% DMSO or 10−6 M Ipsen 5i
for 24 h. On the day of experiment, cells were washed with
phosphate buffered saline for immunohistochemistry (PBS-IH,
137 mM NaCl, 2.7 mM KCl, 1.4 mM KH2PO4, 4.3 mM Na2HPO4,
pH 7.4) and fixed with 4% paraformaldehyde for 15 min. After
blocking with 5% bovine serum albumin (BSA) in PBS-IH for
1 h, cells were incubated with mouse anti-myc 9E10 monoclonal
antibody (Developmental Studies Hybridoma Bank, The Uni-
versity of Iowa, Iowa City, IA, USA) 1:40 diluted in PBS-IH
containing 0.5% BSA for 1 h. Cells were then washed and incu-
bated with Alexa Fluor 488-labeled goat anti-mouse antibody
(Invitrogen, Grand Island, NY, USA) 1:2000 diluted in PBS-IH
containing 0.5% BSA for 1 h. Cells were washed, covered with
Vectashield mounting media (Vector Laboratories, Burlingame,
CA, USA) and a glass coverslip, and dried overnight at 4°C.
Images were taken using a Nikon A1 confocal microscope. All
the steps were performed at room temperature unless mentioned
otherwise.
FLOW CYTOMETRY
HEK293 stable cells and Neuro2a transiently transfected cells were
treated with either 0.1% DMSO or Ipsen 5i (10−6 or 10−5 M)
for 24 h at 37°C. On the day of experiment, cells were washed
with ice-cold PBS-IH, detached, and precipitated by centrifugation
at 500× g for 5 min. Cells were then incubated with antibod-
ies the same way as described above for confocal microscopy.
FIGURE 1 | Schematic representation of MC4R. Naturally occurring mutations of the MC4R characterized in this study are highlighted; mutations that result
in intracellular retention of the MC4R are highlighted in gray whereas mutations that do not interfere with the cell surface expression of the MC4R are
highlighted in dark.
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For immunostaining of MC3R, cells were incubated with HA.11
antibody (Covance, Princeton, NJ, USA) at 1:100 dilutions and
then stained with secondary antibody as described above. Cells
were analyzed using a C6 Accuri Cytometer (Accuri Cytometers,
Ann Arbor, MI, USA). Fluorescence of cells expressing the DMSO-
treated empty vector (pcDNA3.1) was used for background stain-
ing. The expression of the mutants was calculated as percentage of
DMSO-treated WT receptor expression using the following for-
mula: [(mutant− pcDNA3.1)/(WT− pcDNA3.1)× 100%] (31).
INTRACELLULAR cAMP ACCUMULATION ASSAY
HEK293 stable cells and Neuro2A and N1E-115 transiently
transfected cells were treated with 0.1% DMSO or differ-
ent concentrations of Ipsen 5i for 24 h at 37°C. On the
day of experiment, cells were washed twice with warm Way-
mouth’s MB752/1 media (Sigma-Aldrich, St. Louis, MO, USA)
containing 1 mg/ml BSA (Waymouth’s/BSA) and incubated
with Waymouth’s/BSA containing 0.5 mM isobutylmethylxan-
thine (Sigma-Aldrich) for 15 min. Cells were then stimulated
with 10−6 M NDP-MSH for 1 h at 37°C. Intracellular cAMP
was extracted by adding 0.5 M percholoric acid containing
180µg/ml theophylline (Sigma-Aldrich) and neutralized with
0.72 M KOH/0.6 M KHCO3. Cyclic AMP concentration was deter-
mined by RIA (25). The intracellular cAMP accumulation of the
mutants was calculated as percentage of DMSO-treated WT recep-
tor using the formula [mutant/WT× 100%] for HEK293 cells or
the formula [(mutant− pcDNA3.1)/(WT− pcDNA3.1)× 100%]
for Neuro2a and N1E-115 cells.
DATA ANALYSIS
Data were analyzed using GraphPad Prism 4.0 software (San
Diego, CA, USA). The statistical significance of the differences
between DMSO and Ipsen 5i treated cells was assessed by Student’s
t -test.
RESULTS
Ipsen 5i RESCUED THE CELL SURFACE EXPRESSION OF MUTANT MC4Rs
To investigate whether Ipsen 5i acted as a pharmacoperone rescu-
ing the cell surface expression of mutant MC4Rs, we studied 11
mutants (S58C, N62S, I69R, P78L, C84R, G98R, Y157S, W174C,
P260Q, F261S, and C271Y) that have reduced or absent cell sur-
face expression (16, 28, 30) (Figure 1). We first visualized the cell
FIGURE 2 | Ipsen 5i rescued the cell surface expression of intracellularly
retained mutant MC4Rs in HEK293 cells as visualized by confocal
microscopy. HEK293 cells stably expressing WT or mutant MC4Rs were
treated with 10−6 M Ipsen 5i for 24 h and then stained with Alexa Fluor
488-conjugated antibody. Cells were visualized using a Nikon A1 confocal
microscope. Results are representative of three independent experiments.
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FIGURE 3 | Ipsen 5i rescued the cell surface expression of
intracellularly retained mutant MC4Rs in HEK293 cells as quantitated
by flow cytometry. HEK293 cells stably expressing WT or mutant MC4Rs
were treated with 10−5 (A) or 10−6 (B) M Ipsen 5i for 24 h and then stained
with Alexa Fluor 488-conjugated antibody. The immunostaining was
measured using a C6 Accuri Cytometer. The results are expressed as %
DMSO-treated WT cell surface expression level after correction of the
non-specific staining in cells expressing the empty vector. Results are
shown as mean±SEM of at least three independent experiments.
*Significantly different from the DMSO-treated control group, p< 0.05.
surface expression of the 11 mutants stably expressed in HEK293
cells treated with 10−6 M Ipsen 5i using a confocal microscope.
As shown in Figure 2, with 10−6 M Ipsen 5i treatment for 24 h,
the immunostaining of 10 mutants (S58C, N62S, P78L, C84R,
G98R, Y157S, W174C, P260Q, F261S, and C271Y) was dramat-
ically enhanced compared with that of the DMSO-treated con-
trol cells whereas that of one mutant (I69R) was not obviously
changed.
To quantitate the rescuing effect of Ipsen 5i on the cell sur-
face expression of mutant MC4Rs, flow cytometry studies were
performed using HEK293 and Neuro2a cells. HEK293 cells sta-
bly expressing WT or mutant MC4Rs were treated with 10−5 M
(Figure 3A) or 10−6 M (Figure 3B) Ipsen 5i for 24 h. Consis-
tent with confocal microscopy results, the cell surface expression
of 10 mutants (S58C, N62S, P78L, C84R, G98R, Y157S, W174C,
P260Q, F261S, and C271Y) was significantly increased with Ipsen
5i treatment to a level similar to or even higher than that of the
DMSO-treated WT receptor. I69R was not rescued by Ipsen 5i in
HEK293 cells.
FIGURE 4 | Ipsen 5i rescued the cell surface expression of
intracellularly retained mutant MC4Rs in Neuro2a cells. Neuro2a cells
transiently expressing WT or mutant MC4Rs were treated with 10−6 M
Ipsen 5i. Results are shown as mean±SEM of at least three independent
experiments. See the legend to Figure 3 for details.
Neuro2a cells transiently expressing WT or mutant MC4Rs
were treated with 10−6 M Ipsen 5i for 24 h and then were used
for flow cytometry studies. S58C was not further studied in neu-
ronal cells because as described later its function was not rescued
by Ipsen 5i. As shown in Figure 4, the cell surface expression of
eight mutants (N62S, I69R, P78L, C84R, G98R, W174C, P260Q,
and C271Y) was increased with Ipsen 5i treatment compared
with the DMSO-treated control group. The cell surface expres-
sion of I69R was slightly (although significantly) increased in
Neuro2a cells whereas it was not increased in HEK293 cells.
The increase of cell surface expression of F261S was not sta-
tistically significant in Neuro2a cells. One mutant (Y157S) that
was rescued by Ipsen 5i in HEK293 cells was not rescued in
Neuro2a cells.
THE MAJORITY OF THE MUTANT MC4Rs RESCUED WITH Ipsen 5i
COULD RESPOND TO AGONIST STIMULATION WITH INCREASED cAMP
GENERATION
We next investigated whether Ipsen 5i-rescued mutant MC4Rs
were functional in generating cAMP at the cell surface. HEK293
cells stably expressing WT or mutant MC4Rs were incubated with
different concentrations of Ipsen 5i for 24 h, and then stimulated
with 10−6 M NDP-MSH. The intracellular cAMP accumulation
was measured. As shown in Figure 5, the cAMP accumulation of
WT MC4R was decreased by approximately 30% with 10−6 Ipsen
5i treatment and by 80% with 10−5 M Ipsen 5i treatment. We
observed an increase in cAMP accumulation at 10−9 M Ipsen 5i
for C84R and W174C and a maximal increase at a concentration
between 10−8 and 10−6 M for N62S, P78L, C84R, Y15YS, W174C,
P260Q, and C271Y. Unlike most of the mutants that decreased
cAMP accumulation at 10−5 M Ipsen 5i, I69R had a maximal
cAMP accumulation at that concentration. The signaling of S58C
and G98R was not increased by Ipsen 5i.
In Neuro2a cells transiently expressing MC4Rs, we also
observed an increase in cAMP accumulation at 10−9 M Ipsen 5i
and a maximal increase at 10−6 M Ipsen 5i (or at 10−5 M Ipsen 5i
for I69R) in Neuro2a cells (Figure 6A). As shown in Figure 6B,
with 10−6 M Ipsen 5i treatment in Neuro2a cells, seven mutants
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FIGURE 5 | Ipsen 5i rescued the function of intracellularly retained
mutant MC4Rs in HEK293 cells. HEK293 cells stably expressing WT or
mutant MC4Rs were treated with either different concentrations of Ipsen 5i
(A), 10−6 M Ipsen 5i (B), or DMSO as control for 24 h. Cells were washed
twice and stimulated with 10−6 M NDP-MSH for 1 h. Intracellular cAMP
samples were collected and cAMP concentrations were measured using RIA.
The results are expressed as % DMSO-treated WT cAMP production. Data
points are shown as mean±SEM of at least two or three independent
experiments. *Significantly different from the DMSO-treated control group,
p<0.05.
(N62S, I69R, P78L, C84R, W174C, P260Q, and C271Y) had signif-
icantly increased cAMP accumulation whereas signaling of three
mutants (G98R, Y157S, and F261S) was not increased by Ipsen
5i. High concentration of Ipsen 5i did not decrease the cAMP
accumulation of WT or mutant MC4Rs as dramatically as seen
in HEK293 cells (Figure 6A). Our results obtained from N1E-
115 cells were similar with those obtained from Neuro2a cells
(Figure 7).
Ipsen 5i DID NOT AFFECT MUTANT MC4Rs THAT ARE EXPRESSED AT
THE CELL SURFACE
To investigate whether Ipsen 5i rescued the function of mutant
MC4Rs that are expressed at the cell surface but have other defects,
we studied four mutants that are defective in ligand binding
[(∆88-92) (32) (Class III according the classification proposed by
Tao (33)], signaling (D90N and I102S) (29, 34) (Class IV), or with
no obvious defect (N274S) (28) (Class V). As shown in Figures 6B
and 7, 10−6 Ipsen 5i had no effect on the signaling of these four
mutants.
SPECIFICITY OF THE MC4R MUTANT RESCUE
To investigate whether cell impermeable peptide ligands of the
MC4R or cell permeable ligands of other receptors could res-
cue mutant MC4Rs, we studied the effect of two MC4R peptide
agonists (NDP-MSH and α-MSH), one MC4R peptide antagonist
(SHU9119), and one pharmacoperone of δ opioid receptor (nal-
trexone) (35) (Figure 8A) on C84R MC4R. As shown in Figure 8B,
NDP-MSH and α-MSH decreased the signaling of WT MC4R by
approximately 50%. However, none of the four ligands rescued the
signaling of C84R MC4R.
To investigate whether Ipsen 5i specifically rescues mutant
MC4Rs, we studied the effect of Ipsen 5i on one of intracellularly
retained mutant MC3Rs (I335S) (27, 36). As shown in Figure 8C,
Ipsen 5i had no effect on the cell surface expression or signaling of
I335S MC3R.
DISCUSSION
Most of the inactivating mutations in GPCRs causing human dis-
eases result from protein misfolding and subsequent retention and
degradation by the ER quality control system (22). Misrouted
receptors may retain intrinsic function and become functional
when correctly located (37). Pharmacoperones that can perme-
ate plasma membrane specifically stabilize the conformation and
correct the trafficking of misfolded receptors, thus, rescuing the
receptor and curing human diseases (38–41). In the current study,
we identified Ipsen 5i, an antagonist of the MC4R, as a potent
pharmacoperone specifically rescuing the cell surface expression
and function of intracellularly retained mutant MC4Rs.
Our results showed that all 11 intracellularly retained mutants
studied herein could be rescued to the cell surface by Ipsen 5i in at
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FIGURE 6 | Ipsen 5i rescued the function of intracellularly retained
mutant MC4Rs in Neuro2a cells. Neuro2a cells transiently expressing WT
or mutant MC4Rs were treated with either different concentrations of Ipsen
5i (A), 10−6 M Ipsen 5i (B), or DMSO as control. The results are expressed as
% DMSO-treated WT cAMP production after correction of the cAMP
production in cells expressing the empty vector. Data points are
mean±SEM of at least three independent experiments. See the legend to
Figure 5 for other details.
FIGURE 7 | Ipsen 5i rescued the function of intracellularly retained
mutant MC4Rs in N1E-115 cells. N1E-115 cells transiently expressing WT
or mutant MC4Rs were treated with 10−6 M Ipsen 5i or DMSO as control.
The results are expressed as % DMSO-treated WT cAMP production after
correction of the cAMP production in cells expressing the empty vector.
Results are shown as mean±SEM of at least three independent
experiments. See the legend to Figure 5 for details.
least one cell line (Table 1). Y157S could be significantly rescued
in HEK293 cells but not in neuronal cells whereas I69R was par-
tially rescued in neuronal cells but not in HEK293 cells. The effects
of Ipsen 5i on eight mutants were similar between HEK293 and
neuronal cell lines. The cell surface expression of most mutants
treated with Ipsen 5i was increased to at least 50% of or even
similar to that of the DMSO-treated WT receptor. The rescuing
efficacies of Ipsen 5i were different for different mutations. I69R
was the most difficult to rescue because it could only be maximally
rescued with the highest concentration of Ipsen 5i (10−5 M) and
could not be rescued with another pharmacoperone of the MC4R,
ML00253764 (unpublished observations). This suggests that I69R
induces a large change in the receptor conformation that is difficult
to be stabilized.
Eight of the 11 mutants rescued to the cell surface were func-
tional in cAMP production (N62S, I69R, P78L, C84R, Y157S,
W174C, P260Q, and C271Y) in HEK293 cells and seven mutants,
with the exception of Y157S, in neuronal cells (Table 1). These
results suggest that these mutants, although misfolded and
retained intracellularly, retain the ability to bind to agonist and
initiate downstream signaling. Ipsen 5i treatment did not signifi-
cantly increase F261S signaling. G98R, although rescued to the cell
surface, did not respond to NDP-MSH stimulation with increased
cAMP generation, suggesting that this mutant was also defective in
ligand binding and/or signaling. We are also unable to rescue G98R
functionally using a small molecule agonist as the pharmacoper-
one (42). Despite low cell surface expression, S58C has significant
signaling (28), likely due to the presence of spare receptor (33).
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FIGURE 8 | Ipsen 5i specifically rescued mutant MC4Rs and the rescue
action occurred intracellularly. (A) Structures of the ligands studied. The
peptide ligands NDP-MSH and α-MSH are agonists of the MC4R whereas
SHU9119 is an MC4R antagonist. Naltrexone is a small molecule antagonist
of the opioid receptor. Ipsen 5i is a small molecule inverse agonist of the
MC4R. (B) Neuro2a cells transiently expressing WT or C84R MC4R were
treated with different ligands for 24 h (10−5 M NDP-MSH, α-MSH, SHU9119 or
naltrexone or 10−6 M Ipsen 5i). Cells were washed twice and then stimulated
with 10−6 M NDP-MSH for 1 h and intracellular cAMP concentrations were
measured. (C) Neuro2a cells transiently expressing WT or I335S MC3Rs were
treated with 10−6 M Ipsen 5i for 24 h. Then, the cell surface expression and
intracellular cAMP production of MC3Rs were measured. Results are shown
as mean±SEM of at least three independent experiments. *Significantly
different from the DMSO-treated control group, p<0.05.
Ipsen 5i treatment significantly increased cell surface expression
of S58C (Figures 2 and 3). However, its signaling was not increased
and tended to decrease.
The signaling of WT MC4R was dramatically decreased when
treated with 10−5 M Ipsen 5i in HEK293 cells (Figure 5). The
residual Ipsen 5i that had not been washed away presumably still
occupied the binding site of the MC4R and therefore, antagonized
the stimulation of NDP-MSH. Although Ipsen 5i has a high-
affinity with the MC4R (Ki, 2 nM), it has relatively low functional
antagonist potency (77 nM) (24), minimizing its antagonizing
effect on NDP-MSH. Indeed, in our study, 10−6 and 10−7 M Ipsen
5i, which already had significant pharmacoperone rescuing ability,
only decreased the signaling of WT MC4R by approximately 30
or 20% in HEK293 cells, respectively (Figure 5). Interestingly, we
had not observed such dramatic decrease in WT MC4R signaling
in neuronal cells (Figures 6 and 7), suggesting that it might be eas-
ier for Ipsen 5i to dissociate from the MC4R expressed in neuronal
cells.
Ipsen 5i has low affinity for the MC3R (Ki, 400 nM) and there-
fore, we investigated whether Ipsen 5i could rescue misrouted
MC3R mutant I335S. We found that Ipsen 5i did not increase
the cell surface expression or function of I335S MC3R, suggest-
ing that Ipsen 5i was a pharmacoperone specific for the MC4R.
Although Ipsen 5i was a potent pharmacoperone of the MC4R,
it had no effect on mutant MC4Rs defective in ligand binding
or signaling, suggesting that Ipsen 5i could only rescue the func-
tion of the intracellularly retained mutant MC4Rs. As expected,
cell impermeable peptide ligands of the MC4R did not rescue the
function of misrouted mutant MC4R C84R whereas cell perme-
able Ipsen 5i did. Consistent with previous reports on several other
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Table 1 | Summary of the effects of Ipsen 5i on the cell surface
expression and function of WT and mutant MC4Rs.
Mutants HEK293 cells Neuronal cells
Expression Function Expression Function
WT ↑ ↓ − −
S58C ↑ − / /
N62S ↑ ↑ ↑ ↑
I69R − ↑ ↑ ↑
P78L ↑ ↑ ↑ ↑
C84R ↑ ↑ ↑ ↑
G98R ↑ − ↑ −
Y157S ↑ ↑ − −
W174C ↑ ↑ ↑ ↑
P260Q ↑ ↑ ↑ ↑
F261S ↑ / − −
C271Y ↑ ↑ ↑ ↑
↑, increase; ↓, decrease; −, no significant effect; /, not studied herein.
GPCRs (35, 43–45), this observation suggests that only cell per-
meable small compound could act as a pharmacoperone and the
rescuing action occurred intracellularly. Peptide ligands decreased
the signaling of WT MC4R probably by inducing internalization
and down-regulation (NDP-MSH and α-MSH) or by antagoniz-
ing NDP-MSH (SHU9119). Naltrexone, a pharmacoperone of δ
opioid receptor (35), also did not correct the function of C84R
MC4R, suggesting that only ligands for the MC4R could act as
MC4R pharmacoperones.
In summary, Ipsen 5i increased the cell surface expression of all
11 intracellularly retained mutant MC4Rs (100%) studied herein
and eight of the 11 mutants (73%) were functional at the cell sur-
face in at least one cell line. Ipsen 5i could rescue mutant MC4Rs
at a concentration as low as 10−9 M. To our knowledge, it was
the most potent pharmacoperone of the MC4R identified so far.
Future experiments aimed at demonstrating the in vivo efficacy of
this ligand in transgenic animals will represent another important
step toward personalized medicine for treating patients harboring
these MC4R mutations.
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